Drug intelligence / Profile preview

CereKin

Development stage: Discontinued
Lead developer: Elanco
Administration: Injectable

Overview

**CereKin (KB010)** is a biologic interleukin-1 (IL-1) inhibitor developed by Kindred Biosciences for veterinary use in dogs. It was investigated as an injectable therapy to control pain and inflammation associated with **osteoarthritis** in canine patients. The drug aimed to block IL-1 signaling, a key pro-inflammatory cytokine implicated in joint degeneration and pain in osteoarthritis, but its pivotal field study failed to meet the primary endpoint, leading to discontinuation of the program.

Targets

IL1A (Interleukin 1 alpha)

Beyond the preview

Go deeper on CereKin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CereKin.

Explore the full profile